PPL has designed a new class of opioid drugs with unique opiate receptor characteristics never before seen. Other opioids such as morphine, oxycodone, hydrocodone, etc. bind strongly to the mu receptor in the brain and then aggressively agonize that receptor. Mu produces euphoria which leads to abuse and addiction.
PPL’s drugs have high binding affinity at all three opiate receptors (mu, kappa and delta) and more balanced receptor activity than other opioids. This profile results in the first ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects.
Extensive animal testing by prominent scientists at leading institutions has demonstrated that the company’s drugs offer robust pain relief (10 times more potent than morphine) without producing euphoria – which is what leads to abuse and addiction. They also demonstrate no dysphoria, no physical dependence, no withdrawal, no death from overdose (even at 350x the analgesic dosage), only moderate respiratory depression at 150x dosage, no constipation at 100x dose, and no other serious side effects. Also, they can sustain addicted primates without precipitating withdrawal and therefore offer very promising use for addiction therapy. The drugs are orally active and inexpensive to manufacture.
10 TIMES MORE POTENT THAN MORPHINE
NO EUPHORIA OR DYSPHORIA
NO ADDICTION OR PHYSICAL DEPENDENCE
NO DEATH FROM OVERDOSE – (EVEN AT 350X DOSAGE)
We intend to continue to seek complimentary business and investment relationships, out-licensing opportunities and/or co-development opportunities with both domestic and overseas partners as we continue to advance our lead drug candidate through pre-clinical and clinical trials.